Research programme: memory disorders therapy - Dart NeuroScience

Drug Profile

Research programme: memory disorders therapy - Dart NeuroScience

Alternative Names: CREB activators - Dart NeuroScience; DNS 003; DNS 005; Novel 1 - Dart NeuroScience; Novel 2 - Dart NeuroScience; Novel 3 - Dart NeuroScience; Novel 4 - Dart NeuroScience; Novel 5 - Dart NeuroScience; Novel 6 - Dart NeuroScience; Novel 7 - Dart NeuroScience; Novel 8 - Dart NeuroScience; Novel programs - Dart NeuroScience

Latest Information Update: 15 Apr 2013

Price : $50

At a glance

  • Originator Helicon Therapeutics
  • Developer Dart NeuroScience
  • Class Small molecules
  • Mechanism of Action Cyclic AMP response element-binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Memory disorders

Most Recent Events

  • 01 Jan 2012 Helicon Therapeutics has been acquired and merged into Dart NeuroScience
  • 26 Apr 2007 This programme is still in development for Memory disorders in USA
  • 31 Oct 2001 Preclinical development for Memory disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top